Chronic Obstructive Pulmonary Disease

Overview

Journal Lancet

Publisher Elsevier

Specialty General Medicine

Date 2012 Feb 9

PMID 22314182

Citations 461

Authors

Marc Decramer

Wim Janssens

Marc Miravitlles

Affiliations

Soon will be listed here.

Abstract

Chronic obstructive pulmonary disease (COPD) is characterised by progressive airflow obstruction that is only partly reversible, inflammation in the airways, and systemic effects or comorbities. The main cause is smoking tobacco, but other factors have been identified. Several pathobiological processes interact on a complex background of genetic determinants, lung growth, and environmental stimuli. The disease is further aggravated by exacerbations, particularly in patients with severe disease, up to 78% of which are due to bacterial infections, viral infections, or both. Comorbidities include ischaemic heart disease, diabetes, and lung cancer. Bronchodilators constitute the mainstay of treatment: β(2) agonists and long-acting anticholinergic agents are frequently used (the former often with inhaled corticosteroids). Besides improving symptoms, these treatments are also thought to lead to some degree of disease modification. Future research should be directed towards the development of agents that notably affect the course of disease.

Citing Articles

The association between cardiovascular diseases and their subcategories with the severity of chronic obstructive pulmonary disease: a large cross-sectional study based on a Chinese hospital population cohort.

Li T, Chen L, Xu H, Zheng Y, Yang H, Zhao H Front Cardiovasc Med. 2025; 12:1502205.

PMID: 40017517 PMC: 11865066. DOI: 10.3389/fcvm.2025.1502205.

Efficacy of Prophylactic Antibiotics in COPD: A Systematic Review.

Tran A, Ghanem A, More M, Nagy A, Toth A Antibiotics (Basel). 2025; 13(12.

PMID: 39766500 PMC: 11672715. DOI: 10.3390/antibiotics13121110.

COPD in females- Seeing through the smoke.

Sreedevi S, Holla R, Vishak A, Unnikrishnan B, Rekha T, Mithra P Lung India. 2024; 42(1):40-46.

PMID: 39718914 PMC: 11789964. DOI: 10.4103/lungindia.lungindia_366_24.

A CT-Based Lung Radiomics Nomogram for Classifying the Severity of Chronic Obstructive Pulmonary Disease.

Zhou T, Zhou X, Ni J, Guan Y, Jiang X, Lin X Int J Chron Obstruct Pulmon Dis. 2024; 19:2705-2717.

PMID: 39677830 PMC: 11646399. DOI: 10.2147/COPD.S483007.

Lung volume reduction: surgery endobronchial valves.

Ceulemans L, Esendagli D, Cardillo G, Migliore M Breathe (Sheff). 2024; 20(3):240107.

PMID: 39660091 PMC: 11629166. DOI: 10.1183/20734735.0107-2024.

References

Alcorn J, Crowe C, Kolls J . TH17 cells in asthma and COPD. Annu Rev Physiol. 2010; 72:495-516. DOI: 10.1146/annurev-physiol-021909-135926. View

Janssens W, Lehouck A, Carremans C, Bouillon R, Mathieu C, Decramer M . Vitamin D beyond bones in chronic obstructive pulmonary disease: time to act. Am J Respir Crit Care Med. 2009; 179(8):630-6. DOI: 10.1164/rccm.200810-1576PP. View

Decramer M, Cooper C . Treatment of COPD: the sooner the better?. Thorax. 2010; 65(9):837-41. DOI: 10.1136/thx.2009.133355. View

Decramer M, Ferguson G . Clinical safety of long-acting beta2-agonist and inhaled corticosteroid combination therapy in COPD. COPD. 2007; 3(3):163-71. DOI: 10.1080/15412550600830263. View

Mannino D, Buist A . Global burden of COPD: risk factors, prevalence, and future trends. Lancet. 2007; 370(9589):765-73. DOI: 10.1016/S0140-6736(07)61380-4. View

Hurst J, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R . Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010; 363(12):1128-38. DOI: 10.1056/NEJMoa0909883. View

Demedts I, Bracke K, Van Pottelberge G, Testelmans D, Verleden G, Vermassen F . Accumulation of dendritic cells and increased CCL20 levels in the airways of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007; 175(10):998-1005. DOI: 10.1164/rccm.200608-1113OC. View

Barnes P, Shapiro S, Pauwels R . Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J. 2003; 22(4):672-88. DOI: 10.1183/09031936.03.00040703. View

Hogg J, McDonough J, Gosselink J, Hayashi S . What drives the peripheral lung-remodeling process in chronic obstructive pulmonary disease?. Proc Am Thorac Soc. 2009; 6(8):668-72. PMC: 2797069. DOI: 10.1513/pats.200907-079DP. View

10.

Buist A, McBurnie M, Vollmer W, Gillespie S, Burney P, Mannino D . International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet. 2007; 370(9589):741-50. DOI: 10.1016/S0140-6736(07)61377-4. View

11.

Soriano J, Ancochea J, Miravitlles M, Garcia-Rio F, Duran-Tauleria E, Munoz L . Recent trends in COPD prevalence in Spain: a repeated cross-sectional survey 1997-2007. Eur Respir J. 2009; 36(4):758-65. DOI: 10.1183/09031936.00138409. View

12.

Hvidsten S, Storesund L, Wentzel-Larsen T, Gulsvik A, Lehmann S . Prevalence and predictors of undiagnosed chronic obstructive pulmonary disease in a Norwegian adult general population. Clin Respir J. 2010; 4(1):13-21. DOI: 10.1111/j.1752-699X.2009.00137.x. View

13.

Tashkin D, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S . A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008; 359(15):1543-54. DOI: 10.1056/NEJMoa0805800. View

14.

Pillai S, Ge D, Zhu G, Kong X, Shianna K, Need A . A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. PLoS Genet. 2009; 5(3):e1000421. PMC: 2650282. DOI: 10.1371/journal.pgen.1000421. View

15.

Nannini L, Cates C, Lasserson T, Poole P . Combined corticosteroid and long-acting beta-agonist in one inhaler versus inhaled steroids for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2007; (4):CD006826. PMC: 4069257. DOI: 10.1002/14651858.CD006826. View

16.

Casas A, Troosters T, Garcia-Aymerich J, Roca J, Hernandez C, Alonso A . Integrated care prevents hospitalisations for exacerbations in COPD patients. Eur Respir J. 2006; 28(1):123-30. DOI: 10.1183/09031936.06.00063205. View

17.

Barnes P, Celli B . Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009; 33(5):1165-85. DOI: 10.1183/09031936.00128008. View

18.

Monso E, Ruiz J, Rosell A, Manterola J, Fiz J, Morera J . Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med. 1995; 152(4 Pt 1):1316-20. DOI: 10.1164/ajrccm.152.4.7551388. View

19.

Pitta F, Troosters T, Spruit M, Probst V, Decramer M, Gosselink R . Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005; 171(9):972-7. DOI: 10.1164/rccm.200407-855OC. View

20.

Singh S, Amin A, Loke Y . Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med. 2009; 169(3):219-29. DOI: 10.1001/archinternmed.2008.550. View